DoMore Diagnostics, a Norwegian health-tech company, has been making waves in the field of cancer diagnostics with its innovative use of artificial intelligence (AI). The company’s recent financial boost from the European Innovation Council (EIC) of up to 10 million euros is a testament to its potential to revolutionize cancer care.
The EICs funding is part of its broader initiative to support high-impact innovations that can address societal challenges. With a budget of 10 billion EUR, the EIC Fund aims to minimize the risk for private investors and support startups through patient capital. This aligns with the EICs mission to foster deep-tech projects across Europe, including those in health technology.
DoMore Diagnostics’ approach integrates AI to improve the precision of cancer prognostics, aiming to reduce both over- and undertreatment of the disease. Their Histotype Px® Colorectal product is a prime example of this, utilizing digital biomarkers to predict patient outcomes from routine tumour tissue slides. This technology not only promises to enhance patient care but also to streamline the drug development process.
The company’s success is built on a solid scientific foundation, with research contributions from leading universities such as the University of Oslo, Oxford University, and University College of London. The Norwegian Research Council has played a crucial role in supporting DoMore Diagnostics through its strategic ICT Lighthouse projects, which aim to tackle societal challenges using cutting-edge technology.
More Diagnostics exemplifies the transformative potential of AI in healthcare. With substantial financial backing and a clear vision for the future, the company is well-positioned to make a lasting impact on cancer diagnostics and treatment. As AI continues to evolve, it holds the promise of delivering more precise, personalized care, ultimately improving outcomes for cancer patients worldwide.
DoMore Diagnostics’ collaboration with Proscia, a leader in digital pathology, further illustrates its commitment to advancing cancer diagnostics. Together, they aim to make personalized treatment decisions simpler and more accessible for all cancer patients.
The significance of DoMore Diagnostics’ work is underscored by the increasing global burden of cancer. Accurate diagnostics are crucial for effective treatment, and AI offers a new frontier in precision medicine. By analysing tumour tissues at a level of detail beyond human capability, DoMore Diagnostics’ AI algorithms can provide insights that lead to better treatment decisions.
The company’s vision extends beyond its current product pipeline. With the support of the EIC and the Norwegian Research Council, DoMore Diagnostics is poised to continue its trajectory of innovation. The healthcare industry eagerly anticipates the impact that such AI-driven technologies will have on cancer care, potentially ushering in a new era of personalized medicine where treatments are tailored to the individual needs of each patient.
